cas 2252403-82-8|| where to buy 7-Chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione

製品名:7-Chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione

IUPAC Name:7-chloro-6-fluoro-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-1H,2H,3H,4H-pyrido[2,3-d]pyrimidine-2,4-dione

包装単位	有効在庫	価格（USD）
CM337558-100g	in stock	ưǊțț
CM337558-500g	in stock	țȁƎƀ
CM337558-1000g	in stock	ŴƎƎƎ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2252403-82-8 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:2252403-82-8; 分子式:C16H14ClFN4O2; 融点:-; SMILESコード:O=C1N(C2=C(C)C=CN=C2C(C)C)C3=NC(Cl)=C(F)C=C3C(N1)=O; 密度:

: カタログ番号:CM337558; 分子量:348.76; 沸点:; MDL番号:; 保管方法:Keep in a tight container and store at abient temperature

: Sotorasib; Dec. 26, 2023, Amgen announced that the U.S. FDA has completed its review of the company's supplemental New Drug Application seeking full approval of LUMAKRAS (sotorasib).
LUMAKRAS (sotorasib) is an oral, first-in-class therapy indicawithted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) following at least one previous systemic therapy.
Sotorasib is the first approved targeted therapy for patients with tumors with any KRAS mutation, which accounts for approximately 25% of mutations in NSCLC. The U.S. FDA granted the application for sotorasib orphan drug, fast track, priority review, and breakthrough therapy designations.